| BIOMARIN PHAR. DL-,001 | 65.00 / -2.58% |
| Date/Time | 10/23 / 19:50 |
| Chg. / Chg.(%) | -1.72 / -2.58% |
| Bid | - |
| Ask | - |
| Open | 66.87 |
| Previous Close | 66.72 |
| High | 66.87 |
| Low | 65.00 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 5 |
| ISIN | US09061G1013 |
| Security | BM8 |
| Exchange | Düsseldorf |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 64.64 |  |
|
| NASDAQ | 77.5300 |  |
1,257,843 |
| IEX | 77.53 | |
172,247 |
| Cboe US | 77.43 | |
22,110 |
| TradeGate | 65.190 | |
508 |
| Mexico | 1,680.00 |  |
162 |
| Berlin | 67.15 | |
100 |
| London Inter.. | 79.40 | |
47 |
| Frankfurt | 67.2700 | |
30 |
| München | 66.89 | |
0 |
| Düsseldorf | 65.00 | |
0 |
| Stuttgart | 64.810 | |
0 |
| Vienna Globa.. | 65.35 | |
0 |
| gettex | 65.150 | |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire
Real-time